23 May 2018 - - Stockholm, Sweden-based vaccine developer Eurocine Vaccines has completed dosing according to plan in the second clinical study with Immunose FLU, the company said.
Immunose FLU is being developed with the aim to become a modern and effective nasal influenza vaccine.
"In the perspective of this year's severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate," says Dr. Anna-Karin Maltais, chief scientific officer.
Eurocine Vaccines is using its clinically validated technology Endocine to develop a patent protected nasal influenza vaccine for children. The quadrivalent inactivated vaccine candidate Immunose FLU is currently in a Phase I/II study.